Bajaj Healthcare · tone and specificity signals across the available quarters.
Language signals
We are the first company in India to secure SEC recommendation for manufacturing and marketing of syntocinomic tablets and we have also successfully completed the BE studies of surinent tablets and are processing towards the regulatory approval procedures.
The growth rate is around 10 to 15% for the next this year 2027. We can expect 18 to 20% margin profile to maintain on a beta level going forward.
Once we are to a peak and full utilization of plant we can expect anything around 200 to 300 crores of revenue and the margin would be around 18 to 20%.
We have already filed a DMF in UK and Europe and we have already got six CP approval recently over period of in last 6 to 8 months. The first batch of revenue can be expected in FY 28-29.